Evaluation of poly-mechanistic antiangiogenic combinations to enhance cytotoxic therapy response in pancreatic cancer.
Gemcitabine (Gem) has limited clinical benefits in pancreatic ductal adenocarcinoma (PDAC). The present study investigated combinations of gemcitabine with antiangiogenic agents of various mechanisms for PDAC, including bevacizumab (Bev), sunitinib (Su) and EMAP II. Cell proliferation and protein ex...
Main Authors: | Niranjan Awasthi, Changhua Zhang, Winston Ruan, Margaret A Schwarz, Roderich E Schwarz |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2012-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC3377661?pdf=render |
Similar Items
-
Superior antitumor activity of nanoparticle albumin-bound paclitaxel in experimental gastric cancer.
by: Changhua Zhang, et al.
Published: (2013-01-01) -
Smac mimetic-derived augmentation of chemotherapeutic response in experimental pancreatic cancer
by: Schwarz Margaret A, et al.
Published: (2011-01-01) -
Cell proliferation and migration are modulated by Cdk-1-phosphorylated endothelial-monocyte activating polypeptide II.
by: Margaret A Schwarz, et al.
Published: (2012-01-01) -
Antiangiogenic therapy
by: Avitabile T
Published: (2010-05-01) -
Mechanisms of resistance to chemotherapeutic and antiangiogenic drugs as novel targets for pancreatic cancer therapy
by: Anna eTamburrino, et al.
Published: (2013-04-01)